<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33682288</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TGF-β isoforms inhibit hepatitis C virus propagation in transforming growth factor beta/SMAD protein signalling pathway dependent and independent manners.</ArticleTitle>
        <Pagination>
          <StartPage>3498</StartPage>
          <EndPage>3510</EndPage>
          <MedlinePgn>3498-3510</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.16432</ELocationID>
        <Abstract>
          <AbstractText>Transforming growth factor beta (TGF-β) plays an important role in the viral liver disease progression via controlling viral propagation and mediating inflammation-associated responses. However, the antiviral activities and mechanisms of TGF-β isoforms, including TGF-β1, TGF-β2 and TGF-β3, remain unclear. Here, we demonstrated that all of the three TGF-β isoforms were increased in Huh7.5 cells infected by hepatitis C virus (HCV), but in turn, the elevated TGF-β isoforms could inhibit HCV propagation with different potency in infectious HCV cell culture system. TGF-β isoforms suppressed HCV propagation through interrupting several different stages in the whole HCV life cycle, including virus entry and intracellular replication, in TGF-β/SMAD signalling pathway-dependent and TGF-β/SMAD signalling pathway-independent manners. TGF-β isoforms showed additional anti-HCV activities when combined with each other. However, the elevated TGF-β1 and TGF-β2, not TGF-β3, could also induce liver fibrosis with a high expression of type I collagen alpha-1 and α-smooth muscle actin in LX-2 cells. Our results showed a new insight into TGF-β isoforms in the HCV-related liver disease progression.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Li-Li</ForeName>
            <Initials>LL</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian-Rui</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Jia-Li</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mei-Xi</ForeName>
            <Initials>MX</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Nan-Nan</ForeName>
            <Initials>NN</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Rong-Mei</ForeName>
            <Initials>RM</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Hai-Yan</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xue-Kai</ForeName>
            <Initials>XK</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>Biao</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yu-Huan</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Zong-Gen</ForeName>
            <Initials>ZG</Initials>
            <Identifier Source="ORCID">0000-0001-7662-6892</Identifier>
            <AffiliationInfo>
              <Affiliation>CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology of Antibiotics, The National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053781">Transforming Growth Factor beta2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053782">Transforming Growth Factor beta3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072756" MajorTopicYN="N">Protein Conformation, alpha-Helical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051785" MajorTopicYN="N">Smad Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053781" MajorTopicYN="N">Transforming Growth Factor beta2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053782" MajorTopicYN="N">Transforming Growth Factor beta3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">TGF-β isoform</Keyword>
        <Keyword MajorTopicYN="Y">TGF-β signalling pathway</Keyword>
        <Keyword MajorTopicYN="Y">addition</Keyword>
        <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
        <Keyword MajorTopicYN="Y">liver fibrosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33682288</ArticleId>
        <ArticleId IdType="pmc">PMC8034461</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.16432</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Radaev S, Zou Z, Huang T, et al. Ternary complex of transforming growth factor‐beta1 reveals isoform‐specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem. 2010;285:14806‐14814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2863181</ArticleId>
            <ArticleId IdType="pubmed">20207738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lichtman MK, Otero‐Vinas M, Falanga V. Transforming growth factor beta (TGF‐beta) isoforms in wound healing and fibrosis. Wound Repair Regen. 2016;24:215‐222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26704519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ciebiera M, Wlodarczyk M, Wrzosek M, et al. Role of transforming growth factor beta in uterine fibroid biology. Int J Mol Sci. 2017;18:2435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5713402</ArticleId>
            <ArticleId IdType="pubmed">29149020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen J, Gingold JA, Su X. Immunomodulatory TGF‐beta signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25:1010‐1023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31353124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chida T, Ito M, Nakashima K, et al. Critical role of CREBH‐mediated induction of transforming growth factor beta2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. Hepatology. 2017;66:1430‐1443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28621467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kinnman N, Andersson U, Hultcrantz R. In situ expression of transforming growth factor‐beta1‐3, latent transforming growth factor‐beta binding protein and tumor necrosis factor‐alpha in liver tissue from patients with chronic hepatitis C. Scand J Gastroenterol. 2000;35:1294‐1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11199370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hassan M, Selimovic D, Ghozlan H, Abdel‐kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology. 2009;49:1469‐1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19235829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chusri P, Kumthip K, Hong J, et al. HCV induces transforming growth factor beta1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep. 2016;6:22487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4772380</ArticleId>
            <ArticleId IdType="pubmed">26927933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fabregat I, Caballero‐Diaz D. Transforming growth factor‐beta‐induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front Oncol. 2018;8:357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6139328</ArticleId>
            <ArticleId IdType="pubmed">30250825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murata T, Ohshima T, Yamaji M, et al. Suppression of hepatitis C virus replicon by TGF‐beta. Virology. 2005;331:407‐417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15629783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chou YC, Chen ML, Hu CP, et al. Transforming growth factor‐beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology. 2007;46:672‐681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17580335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deng L, Li Y, Huang JM, et al. Effects of p‐CREB‐1 on transforming growth factor‐beta3 auto‐regulation in hepatic stellate cells. J Cell Biochem. 2011;112:1046‐1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21308733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peng Z‐G, Fan BO, Du N‐N, et al. Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology. 2010;52:845‐853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20593456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng J‐J, Li J‐R, Huang M‐H, et al. CD36 is a co‐receptor for hepatitis C virus E1 protein attachment. Sci Rep. 2016;6:21808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4761891</ArticleId>
            <ArticleId IdType="pubmed">26898231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Navarro‐Corcuera A, Lopez‐Zabalza MJ, Martinez‐Irujo JJ, et al. Role of AGAP2 in the profibrogenic effects induced by TGFbeta in LX‐2 hepatic stellate cells. Biochim Biophys Acta Mol Cell Res. 2019;1866:673‐685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30660615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steenbergen RHG, Joyce MA, Thomas BS, et al. Human serum leads to differentiation of human hepatoma cells, restoration of very‐low‐density lipoprotein secretion, and a 1000‐fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology. 2013;58:1907‐1917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23775894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anggakusuma
, Romero‐Brey I, Berger C, et al. Interferon‐inducible cholesterol‐25‐hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology. 2015;62:702‐714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25999047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623‐626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15947137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma LL, Zhang P, Wang HQ, et al. heme oxygenase‐1 agonist CoPP suppresses influenza virus replication through IRF3‐mediated generation of IFN‐alpha/beta. Virology. 2019;528:80‐88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30580124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin. 2004;25:146‐147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14769200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peng Z‐G, Zhao Z‐Y, Li Y‐P, et al. Host apolipoprotein B messenger RNA‐editing enzyme catalytic polypeptide‐like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology. 2011;53:1080‐1089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21480314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patra T, Sasaki R, Meyer K, Ray RB, Ray R. Transforming growth factor beta acts as a regulatory molecule for lipogenic pathways among hepatitis C virus genotype‐specific infections. J Virol. 2019;93:e00811‐19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6714813</ArticleId>
            <ArticleId IdType="pubmed">31243135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang L, Pang Y, Moses HL. TGF‐beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31:220‐227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2891151</ArticleId>
            <ArticleId IdType="pubmed">20538542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110‐113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10390360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amatayakul‐Chantler S, Qian SW, Gakenheimer K, et al. [Ser77]transforming growth factor‐beta 1. Selective biological activity and receptor binding in mink lung epithelial cells. J Biol Chem. 1994;269:27687‐27691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7961688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rienhoff HY Jr, Yeo CY, Morissette R, et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys‐Dietz syndrome. Am J Med Genet A. 2013;161A:2040‐2046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885154</ArticleId>
            <ArticleId IdType="pubmed">23824657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baardsnes J, Hinck CS, Hinck AP, O'Connor‐McCourt MD. TbetaR‐II discriminates the high‐ and low‐affinity TGF‐beta isoforms via two hydrogen‐bonded ion pairs. Biochemistry. 2009;48:2146‐2155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2801812</ArticleId>
            <ArticleId IdType="pubmed">19161338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SK, Barron L, Hinck CS, et al. An engineered transforming growth factor beta (TGF‐beta) monomer that functions as a dominant negative to block TGF‐beta signaling. J Biol Chem. 2017;292:7173‐7188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5409485</ArticleId>
            <ArticleId IdType="pubmed">28228478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim KK, Sheppard D, Chapman HA. TGF‐beta1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10:a022293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880172</ArticleId>
            <ArticleId IdType="pubmed">28432134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang PM, Nikolic‐Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144‐158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30692665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu Y, Zhong J. Innate immunity against hepatitis C virus. Curr Opin Immunol. 2016;42:98‐104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27366996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Negash AA, Ramos HJ, Crochet N, et al. IL‐1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 2013;9:e1003330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3635973</ArticleId>
            <ArticleId IdType="pubmed">23633957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lopez‐Luque J, Bertran E, Crosas‐Molist E, et al. Downregulation of epidermal growth factor receptor in hepatocellular carcinoma facilitates transforming growth factor‐beta‐induced epithelial to amoeboid transition. Cancer Lett. 2019;464:15‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6853171</ArticleId>
            <ArticleId IdType="pubmed">31465839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fan W, Liu T, Chen W, et al. ECM1 prevents activation of transforming growth factor beta, hepatic stellate cells, and fibrogenesis in mice. Gastroenterology. 2019;157:1352‐1367 e1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31362006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schon HT, Weiskirchen R. Immunomodulatory effects of transforming growth factor‐beta in the liver. Hepatobiliary Surg Nutr. 2014;3:386‐406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4273109</ArticleId>
            <ArticleId IdType="pubmed">25568862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tielemans B, Delcroix M, Belge C, Quarck R. TGFbeta and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discov Today. 2019;24:703‐716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30529762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tarantino G, Conca P, Riccio A, et al. Enhanced serum concentrations of transforming growth factor‐beta1 in simple fatty liver: is it really benign?
J Transl Med. 2008;6:72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2611972</ArticleId>
            <ArticleId IdType="pubmed">19038040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ciebiera M, Wlodarczyk M, Wrzosek M, et al. Ulipristal acetate decreases transforming growth factor beta3 serum and tumor tissue concentrations in patients with uterine fibroids. Fertil Steril. 2018;109:501‐507 e502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29525690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krasagakis K, Thölke D, Farthmann B, et al. Elevated plasma levels of transforming growth factor (TGF)‐β1 and TGF‐β2 in patients with disseminated malignant melanoma. Br J Cancer. 1998;77:1492‐1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2150189</ArticleId>
            <ArticleId IdType="pubmed">9652767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grüngreiff K, Reinhold D, Ansorge S. Serum concentrations of sIL‐2R, IL‐6, TGF‐beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon‐alpha. Cytokine. 1999;11:1076‐1080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10623433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoshida K, Matsuzaki K, Murata M, et al. Clinico‐pathological importance of TGF‐beta/phospho‐smad signaling during human hepatic fibrocarcinogenesis. Cancers. 2018;10:183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6025395</ArticleId>
            <ArticleId IdType="pubmed">29874844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fabregat I, Moreno‐Caceres J, Sanchez A, et al. TGF‐beta signalling and liver disease. FEBS J. 2016;283:2219‐2232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26807763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46:48‐57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17596875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burmester JK, Qian SW, Ohlsen D, et al. Mutational analysis of a transforming growth factor‐beta receptor binding site. Growth Factors. 1998;15:231‐242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9570043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zuniga JE, Groppe JC, Cui Y, et al. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform‐dependent. J Mol Biol. 2005;354:1052‐1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16289576</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
